Literature DB >> 25104666

Malaria burden and control in Bangladesh and prospects for elimination: an epidemiological and economic assessment.

Ubydul Haque1, Hans J Overgaard2, Archie C A Clements3, Douglas E Norris4, Nazrul Islam5, Jahirul Karim5, Shyamal Roy5, Waziul Haque6, Moktadir Kabir7, David L Smith8, Gregory E Glass9.   

Abstract

BACKGROUND: Malaria is endemic in 13 of 64 districts in Bangladesh. About 14 million people are at risk. Some evidence suggests that the prevalence of malaria in Bangladesh has decreased since the the Global Fund to Fight AIDS, Tuberculosis and Malaria started to support the National Malaria Control Program (NMCP) in 2007. We did an epidemiological and economic assessment of malaria control in Bangladesh.
METHODS: We obtained annually reported, district-level aggregated malaria case data and information about disbursed funds from the NMCP. We used a Poisson regression model to examine the associations between total malaria, severe malaria, malaria-attributable mortality, and insecticide-treated net coverage. We identified and mapped malaria hotspots using the Getis-Ord Gi* statistic. We estimated the cost-effectiveness of the NMCP by estimating the cost per confirmed case, cost per treated case, and cost per person of insecticide-treated net coverage.
FINDINGS: During the study period (from Jan 1, 2008, to Dec 31, 2012) there were 285,731 confirmed malaria cases. Malaria decreased from 6.2 cases per 1000 population in 2008, to 2.1 cases per 1000 population in 2012. Prevalence of all malaria decreased by 65% (95% CI 65-66), severe malaria decreased by 79% (78-80), and malaria-associated mortality decreased by 91% (83-95). By 2012, there was one insecticide-treated net for every 2.6 individuals (SD 0.20). Districts with more than 0.5 insecticide-treated nets per person had a decrease in prevalence of 21% (95% CI 19-23) for all malaria, 25% (17-32) for severe malaria, and 76% (35-91) for malaria-associated mortality among all age groups. Malaria hotspots remained in the highly endemic districts in the Chittagong Hill Tracts. The cost per diagnosed case was US$0.39 (SD 0.02) and per treated case was $0.51 (0.27); $0.05 (0.04) was invested per person per year for health education and $0.68 (0.30) was spent per person per year for insecticide-treated net coverage.
INTERPRETATION: Malaria elimination is an achievable prospect in Bangladesh and failure to push for elimination nearly ensures a resurgence of disease. Consistent financing is needed to avoid resurgence and maintain elimination goals. FUNDING: None.
Copyright © 2014 Haque et al. Open Access article distributed under the terms of CC BY-NC-ND. Published by .. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25104666     DOI: 10.1016/S2214-109X(13)70176-1

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  33 in total

1.  Plasmodium falciparum Genetic Diversity in Bangladesh Does Not Suggest a Hypoendemic Population Structure.

Authors:  Mohammad Shafiul Alam; Rubayet Elahi; Abu Naser Mohon; Hasan Mohammad Al-Amin; Mohammad Golam Kibria; Wasif A Khan; Hamida Khanum; Rashidul Haque
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

2.  Seasonal dynamics and microgeographical spatial heterogeneity of malaria along the China-Myanmar border.

Authors:  Yue Hu; Guofa Zhou; Yonghua Ruan; Ming-Chieh Lee; Xin Xu; Shuang Deng; Yao Bai; Jie Zhang; James Morris; Huaie Liu; Ying Wang; Qi Fan; Peipei Li; Yanrui Wu; Zhaoqing Yang; Guiyun Yan; Liwang Cui
Journal:  Acta Trop       Date:  2016-01-23       Impact factor: 3.112

3.  Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh.

Authors:  Benedikt Ley; Mohammad Shafiul Alam; Nora Engel; Cristian Ghergu; Mohammad Abdul Matin; Mohammad Golam Kibria; Kamala Thriemer; Ric N Price; Xavier C Ding; Rosalind E Howes; Sandra Incardona
Journal:  Malar J       Date:  2021-05-12       Impact factor: 2.979

4.  Prevalence of Malaria and Leptospirosis Co-Infection among Febrile Patients: A Systematic Review and Meta-Analysis.

Authors:  Polrat Wilairatana; Wanida Mala; Pongruj Rattaprasert; Kwuntida Uthaisar Kotepui; Manas Kotepui
Journal:  Trop Med Infect Dis       Date:  2021-07-03

5.  Genetic diversity of Plasmodium vivax in clinical isolates from Bangladesh.

Authors:  Mohammad Golam Kibria; Rubayet Elahi; Abu Naser Mohon; Wasif A Khan; Rashidul Haque; Mohammad Shafiul Alam
Journal:  Malar J       Date:  2015-07-11       Impact factor: 2.979

6.  Role of underappreciated vectors in malaria transmission in an endemic region of Bangladesh-India border.

Authors:  Hasan Mohammad Al-Amin; Rubayet Elahi; Abu Naser Mohon; Mohammad Abdullah Heel Kafi; Sumit Chakma; Jennifer S Lord; Wasif A Khan; Rashidul Haque; Douglas E Norris; Mohammad Shafiul Alam
Journal:  Parasit Vectors       Date:  2015-04-01       Impact factor: 3.876

7.  Spatio-temporal distribution of malaria and its association with climatic factors and vector-control interventions in two high-risk districts of Nepal.

Authors:  Meghnath Dhimal; Robert B O'Hara; Ramchandra Karki; Garib D Thakur; Ulrich Kuch; Bodo Ahrens
Journal:  Malar J       Date:  2014-11-25       Impact factor: 2.979

8.  Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009-2013).

Authors:  Abu Naser Mohon; Mohammad Shafiul Alam; Abebe Genetu Bayih; Asongna Folefoc; Dea Shahinas; Rashidul Haque; Dylan R Pillai
Journal:  Malar J       Date:  2014-11-18       Impact factor: 2.979

Review 9.  Insights into the first seven-months of COVID-19 pandemic in Bangladesh: lessons learned from a high-risk country.

Authors:  Md Hasanul Banna Siam; Md Mahbub Hasan; Shazed Mohammad Tashrif; Md Hasinur Rahaman Khan; Enayetur Raheem; Mohammad Sorowar Hossain
Journal:  Heliyon       Date:  2021-06-25

10.  Using structured additive regression models to estimate risk factors of malaria: analysis of 2010 Malawi malaria indicator survey data.

Authors:  James Chirombo; Rachel Lowe; Lawrence Kazembe
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.